Edwards Lifesciences Corp
EWAPI behind this page
EW Q1 2026 request
Playground key active
/api/financials?ticker=EW&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 1,648.6 | 1,412.7 | +16.7% |
Show Product Lines breakouts |
|||
| Surgical | 276.2 | 250.9 | +10.1% |
| Transcatheter Aortic Valve Replacement | 1,197.3 | 1,046.6 | +14.4% |
| Transcatheter Mitral and Tricuspid Therapies | 175.1 | 115.2 | +52.0% |
Show Business Segments breakouts |
|||
| Europe · Operating Segments | 442.6 | 341.8 | +29.5% |
| Japan · Operating Segments | 90.6 | 81.8 | +10.8% |
| Rest of World · Operating Segments | 177.8 | 150.2 | +18.4% |
| United States · Operating Segments | 937.6 | 838.9 | +11.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,648.6 | 1,412.7 | +16.7% |
| Cost of Revenue | 362.6 | 301.6 | +20.2% |
Show Business Segments breakouts |
|||
| Europe · Operating Segments | 93.6 | 82.2 | +13.9% |
| Japan · Operating Segments | 14.3 | 12.3 | +16.3% |
| Rest of World · Operating Segments | 47.6 | 39.8 | +19.6% |
| United States · Operating Segments | 172 | 146 | +17.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 2.5 | -10.2 | +124.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 327.5 | 280.3 | +16.8% |
| Gross Profit | 1,286 | 1,111.1 | +15.7% |
| Selling, General & Administrative | 522.2 | 465.7 | +12.1% |
Show Business Segments breakouts |
|||
| Europe · Operating Segments | 71.8 | 73.4 | -2.2% |
| Japan · Operating Segments | 15.9 | 16.4 | -3.0% |
| Rest of World · Operating Segments | 48 | 42.1 | +14.0% |
| United States · Operating Segments | 154.1 | 133.2 | +15.7% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 289.8 | 265.1 | +9.3% |
| Research & Development | 263.3 | 254.6 | +3.4% |
| Litigation Settlement Expense | 37.1 | 10.9 | +240.4% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 37.1 | 10.9 | +240.4% |
| Other Operating Income Expense Net | -14.2 | -19.1 | +25.7% |
| Operating Income | 477.6 | 394.8 | +21.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,002.1 | 888.8 | +12.7% |
| Interest Income | -33.5 | -36.5 | +8.2% |
| Variable Interest Entity Loss On Impairment | 123.6 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Not Primary Beneficiary · Medical Device Company February 2019 Investment | 123.6 | — | — |
| Other Non-Operating Income (Expense) | -71.5 | -2.6 | -2650.0% |
Show Equity Components breakouts |
|||
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -1.6 | -1.7 | +5.9% |
| Income Before Taxes | 459 | 433.9 | +5.8% |
| Income Tax Expense (Benefit) | 78.3 | 70.3 | +11.4% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -0.8 | 2.7 | -129.6% |
| Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | 3.9 | 4.2 | -7.1% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 0.4 | 0.4 | 0.0% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 380.7 | 363.6 | +4.7% |
| Net Income | 380.7 | 356.4 | +6.8% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1.7 | 7.5 | -122.7% |
| Accumulated Net Unrealized Investment Gain Loss · Reclassification Out Of Accumulated Other Comprehensive Income | 12.2 | 12.8 | -4.7% |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 1.2 | 1.3 | -7.7% |
| Retained Earnings | 380.7 | 358 | +6.3% |
| Net Income | 380.7 | 358 | +6.3% |
| Income Loss From Continuing Operations Per Basic Share | 0.66 | 0.62 | +6.5% |
| EPS (Basic) | 0.66 | 0.61 | +8.2% |
| Income Loss From Continuing Operations Per Diluted Share | 0.66 | 0.62 | +6.5% |
| EPS (Diluted) | 0.66 | 0.61 | +8.2% |
| Wtd Avg Shares (Basic) | 579.2 | 586.9 | -1.3% |
| Wtd Avg Shares (Diluted) | 580.7 | 587.8 | -1.2% |
| Total Costs & Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -494.8 | -486.2 | -1.8% |
| Non-Operating Income (Expense) | -18.6 | 39.1 | -147.6% |
| Comprehensive Income | 397.7 | 348 | +14.3% |
| Other Comprehensive Income | 17 | -10 | +270.0% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 17 | -10 | +270.0% |
| Interest Income Expense Net | 33.5 | 36.5 | -8.2% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Europe · Operating Segments | 235.3 | 194.5 | +21.0% |
| Japan · Operating Segments | 66.4 | 57.7 | +15.1% |
| Rest of World · Operating Segments | 89.7 | 77.5 | +15.7% |
| United States · Operating Segments | 610.7 | 559.1 | +9.2% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,002.1 | 888.8 | +12.7% |
| Foreign Currency Transaction Gain Loss Before Tax (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 7.4 | 7.3 | +1.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 2,445.5 | — | — |
| Short-Term Investments | 1,226 | — | — |
| Accounts Receivable | 775.7 | — | — |
| Other Receivables Net Current | 197.3 | — | — |
| Inventory | 1,119 | — | — |
| Prepaid Expense Current | 135.7 | — | — |
| Other Assets Current | 329.5 | — | — |
| Total Current Assets | 6,228.7 | — | — |
| Non-Current Assets | |||
| Long Term Investments | 285.6 | — | — |
| Property, Plant & Equipment | 1,823.1 | — | — |
| Operating Lease Right-of-Use Assets | 99.3 | — | — |
| Goodwill | 1,819.6 | — | — |
| Deferred Tax Assets | 1,098.1 | — | — |
| Other Non-Current Assets | 738.9 | — | — |
| Total Assets | 13,321.2 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 1,227.9 | — | — |
| Current Liabilities | |||
| Accounts Payable | 181.1 | — | — |
| Accrued And Other Liabilities Current | 1,203.6 | — | — |
| Operating Lease Liability Current | 24.3 | — | — |
| Total Current Liabilities | 1,409 | — | — |
| Non-Current Liabilities | |||
| Long-Term Debt | 598.5 | — | — |
| Operating Lease Liabilities | 80.1 | — | — |
| Liability For Uncertain Tax Positions Noncurrent | 555.4 | — | — |
| Other Non-Current Liabilities | 350.7 | — | — |
| Total Liabilities | 2,993.7 | — | — |
| Stockholders' Equity | |||
| Common Stock | 660 | — | — |
| Additional Paid In Capital Common Stock | 2,781.5 | — | — |
| Retained Earnings | 14,621.2 | — | — |
| Accumulated Other Comprehensive Income | -221.3 | — | — |
| Treasury Stock Common Value | -7,513.9 | — | — |
| Total Stockholders' Equity | 10,327.5 | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | 1 | — | — |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 8.4 | — | — |
| Accumulated Net Unrealized Investment Gain Loss | -1.2 | — | — |
| Accumulated Other Comprehensive Income | -221.3 | — | — |
| Accumulated Translation Adjustment | -229.5 | — | — |
| Additional Paid In Capital | 2,781.5 | — | — |
| Common Stock | 660 | — | — |
| Retained Earnings | 14,621.2 | — | — |
| Treasury Stock Common | -7,513.9 | — | — |
| Total Liabilities & Equity | 13,321.2 | — | — |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 40.9 | 36.6 | +11.7% |
| Operating Lease Right Of Use Asset Amortization Expense | 6.5 | 6.1 | +6.6% |
| Stock-Based Compensation | 45.4 | 40.2 | +12.9% |
| Gain Loss On Investments | 3.5 | 12.5 | -72.0% |
| Increase Decrease In Deferred Income Taxes | 9.4 | -24.3 | +138.7% |
| Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss | -65.2 | — | — |
| Asset Impairment Charges | 123.6 | — | — |
| Other Non-Cash Items | 0.5 | 3.6 | -86.1% |
| Increase Decrease In Accounts And Other Receivables | -117.9 | -43.7 | -169.8% |
| Change in Inventory | -1.6 | -0.1 | -1500.0% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -347.1 | -103.4 | -235.7% |
| Increase Decrease In Accrued Income Taxes Payable | 41.9 | 51.2 | -18.2% |
| Change in Prepaid & Other Assets | -8.7 | 10.6 | -182.1% |
| Increase Decrease In Legal Settlement Accrual | -50 | -36.7 | -36.2% |
| Increase Decrease In Other Operating Capital Net | -18.1 | -28.6 | +36.7% |
| Net Cash from Operations | 43.8 | 280.4 | -84.4% |
| Investing Activities | |||
| Capital Expenditures | -64.9 | -56 | -15.9% |
| Payments To Acquire Interest In Subsidiaries And Affiliates | -6.3 | — | — |
| Payments To Acquire Held To Maturity Securities | -12.5 | -12.8 | +2.3% |
| Proceeds From Sale And Maturity Of Held To Maturity Securities | 12.5 | 17.7 | -29.4% |
| Purchases of Investments | -641.1 | -634.5 | -1.0% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 710.1 | 827.9 | -14.2% |
| Payments To Acquire Businesses Net Of Cash Acquired Excluding Options | -35.1 | — | — |
| Payments To Acquire Receivables | -55.2 | -17.8 | -210.1% |
| Other Investing Activities | -0.3 | 0.1 | -400.0% |
| Net Cash from Investing | -92.8 | 85.3 | -208.8% |
| Financing Activities | |||
| Share Repurchases | -421.8 | -258.6 | -63.1% |
| Payments For Equity Forward Contract Related To Accelerated Share Repurchase Agreement | -100 | -50 | -100.0% |
| Proceeds From Stock Plans | 68.9 | 49.9 | +38.1% |
| Proceeds From Payments For Other Financing Activities | 1.7 | 0.7 | +142.9% |
| Net Cash from Financing | -451.2 | -258 | -74.9% |
| Supplemental | |||
| Unpaid Capital Expenditures | 39.9 | 31.2 | +27.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 8.2 | -17.7 | +146.3% |
| Net Change in Cash | -492 | 90 | -646.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,447.5 | 3,148.8 | -22.3% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.